Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma.
delta AFP score
hepatocellular carcinoma
liver transplantation
microvascular invasion
recurrence
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
24
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Microvascular invasion (MVI) is one of the main prognostic factors of hepatocellular carcinoma (HCC) after liver transplantation (LT), but its occurrence is unpredictable before surgery. The alpha fetoprotein (AFP) model (composite score including size, number, AFP), currently used in France, defines the selection criteria for LT. This study's aim was to evaluate the preoperative predictive value of AFP SCORE progression on MVI and overall survival during the waiting period for LT. Data regarding LT recipients for HCC from 2007 to 2015 were retrospectively collected from a single institutional database. Among 159 collected cases, 34 patients progressed according to AFP SCORE from diagnosis until LT. MVI was shown to be an independent histopathological prognostic factor according to Cox regression and competing risk analysis in our cohort. AFP SCORE progression was the only preoperative predictive factor of MVI (OR = 10.79 [2.35-49.4];
Identifiants
pubmed: 35401038
doi: 10.3389/ti.2022.10412
pii: 10412
pmc: PMC8983829
doi:
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10412Informations de copyright
Copyright © 2022 Herrero, Boivineau, Cassese, Assenat, Riviere, Faure, Bedoya, Panaro, Guiu, Navarro and Pageaux.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534
pubmed: 28210698
World J Gastrointest Oncol. 2019 Apr 15;11(4):322-334
pubmed: 31040897
Liver Transpl. 2015 Oct;21(10):1250-8
pubmed: 26183802
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
Hepatology. 2014 Mar;59(3):1144-65
pubmed: 24716201
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
HPB (Oxford). 2010 Feb;12(1):56-61
pubmed: 20495646
J Hepatol. 2016 Feb;64(2):433-485
pubmed: 26597456
Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):91-102
pubmed: 32933351
Trends Genet. 2016 Jun;32(6):360-371
pubmed: 27129983
Liver Transpl. 2004 Apr;10(4):534-40
pubmed: 15048797
Liver Int. 2017 May;37(5):717-726
pubmed: 28199760
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
Sci Rep. 2019 Mar 7;9(1):3781
pubmed: 30846792
Ann Surg Oncol. 2008 Apr;15(4):1001-7
pubmed: 18236119
J Hepatol. 2015 May;62(5):1131-40
pubmed: 25529622
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Sci Rep. 2017 Mar 09;7:44036
pubmed: 28276470
Am J Gastroenterol. 2006 Mar;101(3):524-32
pubmed: 16542289
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217
pubmed: 28053342
Transpl Int. 2019 Feb;32(2):163-172
pubmed: 30152891
World J Hepatol. 2016 Jul 28;8(21):881-90
pubmed: 27478538
Eur J Nucl Med Mol Imaging. 2016 May;43(5):852-859
pubmed: 26577938
Liver Transpl. 2011 Oct;17 Suppl 2:S44-57
pubmed: 21695773
Arch Surg. 2008 Feb;143(2):182-8; discussion 188
pubmed: 18283144
Ann Surg Oncol. 2013 Jan;20(1):325-39
pubmed: 23149850
Liver Int. 2019 Aug;39(8):1478-1489
pubmed: 31131974
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Clin Nucl Med. 2011 Dec;36(12):1092-7
pubmed: 22064078
Hepatology. 2001 Dec;34(6):1128-34
pubmed: 11732002
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Gastroenterology. 2004 Nov;127(5 Suppl 1):S268-76
pubmed: 15508093
J Hepatol. 2017 Mar;66(3):552-559
pubmed: 27899297
J Clin Oncol. 2009 Jan 20;27(3):446-52
pubmed: 19064965
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Liver Int. 2016 Nov;36(11):1657-1667
pubmed: 27169841
Lancet. 2009 Jan 31;373(9661):423-31
pubmed: 19186274
Hepatology. 2012 Jul;56(1):149-56
pubmed: 22271250
Am J Transplant. 2010 Jan;10(1):129-37
pubmed: 20070666
J Am Coll Surg. 2015 Apr;220(4):416-27
pubmed: 25690672
Int J Hepatol. 2012;2012:893103
pubmed: 22792474
J Gastrointest Cancer. 2020 Dec;51(4):1127-1132
pubmed: 32845425